Literature DB >> 21879271

The additional value of lymphatic mapping with routine SPECT/CT in unselected patients with clinically localized melanoma.

Hidde J Veenstra1, Lenka Vermeeren, Renato A Valdés Olmos, Omgo E Nieweg.   

Abstract

PURPOSE: To investigate whether single photon emission computed tomography camera with integrated radiographic computed tomography (SPECT/CT) is of additional value compared to conventional lymphoscintigraphy in routine lymphatic mapping in patients with melanoma.
METHODS: Thirty-five unselected patients with a primary melanoma who were scheduled for wide local excision and sentinel node biopsy underwent conventional lymphoscintigraphy and subsequently SPECT/CT. We determined whether SPECT/CT showed additional sentinel nodes, whether it provided better information on the location of the sentinel nodes, and whether this additional anatomic information led to a change in the planned surgical approach.
RESULTS: SPECT/CT depicted the same 69 sentinel nodes as conventional lymphoscintigraphy in all 35 patients plus found eight additional sentinel nodes in seven patients (20%). In two of these patients (5.7%), an additional nodal basin had to be explored to find the extra sentinel nodes. SPECT/CT provided additional anatomic information that was helpful to the surgeon in 11 patients (31%) and led to an adjustment of the surgical approach in 10 patients (29%).
CONCLUSIONS: SPECT/CT provided relevant additional information in 16 (46%) of the 35 patients. Routine use of SPECT/CT in addition to conventional lymphoscintigraphy is recommended in melanoma patients undergoing lymphatic mapping.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21879271     DOI: 10.1245/s10434-011-2031-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  8 in total

1.  Sentinel lymph node excision with or without preoperative hybrid single-photon emission computed tomography/computed tomography (SPECT/CT) in melanoma: study protocol for a multicentric randomized controlled trial.

Authors:  Ingo Stoffels; Ken Herrmann; Jan Rekowski; Philipp Jansen; Dirk Schadendorf; Andreas Stang; Joachim Klode
Journal:  Trials       Date:  2019-02-04       Impact factor: 2.279

Review 2.  Melanoma and nuclear medicine.

Authors:  Andrés Perissinotti; Sergi Vidal-Sicart; Omgo Nieweg; Renato Valdés Olmos
Journal:  Melanoma Manag       Date:  2014-09-05

3.  Extraordinary Lymph Drainage in Cutaneous Malignant Melanoma and the Value of Hybrid Imaging: A Case Report.

Authors:  Lindsay Brammen; Jakob Nedomansky; Werner Haslik; Anton Staudenherz
Journal:  Nucl Med Mol Imaging       Date:  2014-05-27

Review 4.  Clinical utilities and biological characteristics of melanoma sentinel lymph nodes.

Authors:  Dale Han; Daniel C Thomas; Jonathan S Zager; Barbara Pockaj; Richard L White; Stanley Pl Leong
Journal:  World J Clin Oncol       Date:  2016-04-10

5.  Combined analysis of phase III trials evaluating [⁹⁹mTc]tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma.

Authors:  Vernon K Sondak; Dennis W King; Jonathan S Zager; Schlomo Schneebaum; Julian Kim; Stanley P L Leong; Mark B Faries; Bruce J Averbook; Steve R Martinez; Christopher A Puleo; Jane L Messina; Lori Christman; Anne M Wallace
Journal:  Ann Surg Oncol       Date:  2012-10-03       Impact factor: 5.344

Review 6.  Melanoma & nuclear medicine: new insights & advances.

Authors:  Andrés Perissinotti; Daphne Dd Rietbergen; Sergi Vidal-Sicart; Ana A Riera; Renato A Valdés Olmos
Journal:  Melanoma Manag       Date:  2018-06-28

Review 7.  Re-evaluation of Sentinel Lymph Node Biopsy for Melanoma.

Authors:  Steven Morrison; Dale Han
Journal:  Curr Treat Options Oncol       Date:  2021-02-09

8.  Prognostic Value of Multiple Draining Lymph Node Basins in Melanoma: A Matched-Pair Analysis Based on the John Wayne Cancer Institute Experience.

Authors:  J Harrison Howard; Junko J Ozao-Choy; Jason M Hiles; Myung-Shin Sim; Mark B Faries
Journal:  Front Oncol       Date:  2017-08-14       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.